TD Cowen Reiterates Buy Rating on Syros Pharmaceuticals (SYRS)

TD Cowen analyst Phil Nadeau reiterated a Buy rating on Syros Pharmaceuticals (NASDAQ: SYRS).

The analyst commented, "SYRS has discontinued the SELECT-AML-1 trial after results of a prespecified interim found similar CR/CRi rates between study arms and determined the trial was unlikely to succeed. While disappointing, we note that the read through to the pivotal MDS trial is limited. With aza monotherapy as the comparator in MDS the bar is lower, and SELECT MDS has passed a futility analysis. Remain Buy."

For an analyst ratings summary and ratings history on Syros Pharmaceuticals click here. For more ratings news on Syros Pharmaceuticals click here.

Shares of Syros Pharmaceuticals closed at $5.01 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy